Skip to main content

Arrowhead Receives Notice of Allowance on Patent Application Covering Delivery Tech

Premium

Arrowhead Research this week announced that it has received a notice of allowance from the US Patent and Trademark Office that it will be granted a patent on an application covering its dynamic polyconjugate delivery technology.

The patent application, No. 20120165393, is entitled “Peptide-based In Vivo siRNA Delivery System” and claims the targeted delivery of RNAi oligos to hepatocytes when administered along with co-targeted melittin delivery peptides.

The peptides, the patent application indicates, enable cellular membrane penetration.

The patent application, Arrowhead noted, specifically covers the delivery technology being used with the company’s preclinical hepatitis B therapy ARC-520, which is slated to enter phase I testing this year (GSN 2/14/2013).

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.